15 Open, multicenter, randomized, controlled trial to compare safety and efficacy of r-hIFN beta 1a alone or in combination with ribavirin in HCV naiv patients

497 An open-label, multicenter study of

497 An open-label, multicenter study of the efficacy and safety of peginterferon alfa-2A (40KD) (PEGASYS®), alone or in combination with ribavirin (COPEGUS®), in patients with HIV/HCV coinfection

✍ E. Ortega; A. Martin; C. Barros; K. Aguirrebengoa; J. Gonzalez; A. Garcia; R. Ru 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 62 KB

187 Efficacy and safety of 22 weeks of m

187 Efficacy and safety of 22 weeks of maintenance therapy with peginterferon alfa-2A (40KD) (PEGASYS™) alone versus peginterferon alfa-2A (40KD) plus ribavirin(COPEGUS™) in naive patients with chronic hepatitis C and genotype 1 who responded to a 24-week course of peginterferon alfa-2A (40KD) plus ribavirin: an open, multicenter, randomized trial

✍ Jean-Pierre Bronowicki; Denis Ouzan; Arnaud Tzanck; Tarik Asselah; Herve Desmora 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 233 KB

A multicenter, randomized, open-label, c

A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus

✍ Mary Korytkowski; David Bell; Carol Jacobsen; Rudee Suwannasari; FlexPen® Study 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 99 KB

Efficacy and safety of a fixed-ratio com

Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes

✍ Gough, Stephen C L; Bode, Bruce; Woo, Vincent; Rodbard, Helena W; Linjawi, Sulta 📂 Article 📅 2014 🏛 Elsevier 🌐 English ⚖ 284 KB

Efficacy and safety of a fixed-ratio com

Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes

✍ Gough, Stephen C L; Bode, Bruce; Woo, Vincent; Rodbard, Helena W; Linjawi, Sulta 📂 Article 📅 2014 🏛 Elsevier 🌐 English ⚖ 284 KB

## Background: A fixed-ratio combination of the basal insulin analogue insulin degludec and the glucagon-like peptide-1 (glp-1) analogue liraglutide has been developed as a once-daily injection for the treatment of type 2 diabetes. we aimed to compare combined insulin degludec-liraglutide (ideglira

53 POSTER A phase II, multicenter, rando

53 POSTER A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab (Avastin®) in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride (Tarceva®) compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer

✍ R. Herbst; V. O'Neill; L. Fehrenbacher; C. Belani; P. Bonomi; L. Hart; O. Melnyk 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 59 KB